BioSource Gets Rights to Market Test Kit
- Share via
BioSource Industries Inc. of Camarillo has obtained worldwide marketing rights to a test kit for the measurement of Serum Amyloid A, a reagent used in diagnosing such diseases as rheumatoid arthritis as well as secondary infections associated with cystic fibrosis and AIDS.
The kit gives BioSource “an excellent opportunity to market a unique test for what we believe could become a substantial market,” said James Chamberlain, BioSource’s chief executive officer. He said the rights were obtained for an undisclosed amount from Immunoplex Inc. of Omaha, Neb.
Chamberlain said he expects BioSource’s already announced merger with Tago Inc. of San Francisco to become effective in November. He said the newly merged company, to be named BioSource International Inc., will be based in Camarillo and will be traded on NASDAQ under the symbol TAGO.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
